DA 1241

Drug Profile

DA 1241

Alternative Names: DA-1241

Latest Information Update: 26 May 2017

Price : $50

At a glance

  • Originator Dong-A ST
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action GPR119 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 29 Mar 2017 Phase-I clinical trials in Type-2 diabetes mellitus (In volunteers) in South Korea (NCT03061981)
  • 01 Mar 2017 Dong-A ST plans a phase I trial for Type-2 diabetes mellitus (In volunteers) (NCT03061981)
  • 31 Dec 2014 Diabetes therapeutics is available for licensing as of 31 Dec 2014. http://en.donga-st.com/Pass.da?viewPath=/b03/researchClinicalChallenge
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top